You're right looking at Healius figures.
Reason why it would be interesting to know if AFR is talking about EBITDA or EBIT.
Just talking about Healius, interesting to see its valuation : EV/EBITDA of 30 x FY 20 (and 24 x FY 19). Perhaps due to a low basis of earnings (strong rebound during Q1 21).
However, most of Healius results come from the diagnostics business, while QScan is more radiology related, if I understood correctly. So I am interested if someone has a better (listed) comparison for Q Scan.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$10.57 |
Change
0.390(3.83%) |
Mkt cap ! $10.35B | |||
| Open | High | Low | Value | Volume |
| $10.24 | $10.65 | $10.22 | $1.876M | 178.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2673 | $10.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.57 | 5322 | 1 |
View Market Depth
| Last trade - 16.12pm 25/07/2025 (20 minute delay) ? |
| IFT (ASX) Chart |